10-K: Kimball Electronics Navigates Market Headwinds, Restructures for Future Growth

Kimball Electronics reports a 13% net sales decrease in fiscal year 2025, driven by program losses and customer overstocking, while executing strategic restructuring and capacity expansions.

Summary

• Net sales for fiscal year 2025 decreased by 13% to $1,486.7 million compared to $1,714.5 million in fiscal year 2024.
• Net income for fiscal year 2025 was $17.0 million, or $0.68 per diluted share, a 17.2% decrease from $20.5 million, or $0.81 per diluted share, in fiscal year 2024.
• Gross profit as a percentage of net sales declined to 7.0% in fiscal year 2025 from 8.2% in fiscal year 2024.
• Sales decreased across all end market verticals: Automotive (down 11%), Medical (down 7%), and Industrial (down 24%).
• The company completed the divestiture of its GES business on July 31, 2024, recording a pre-tax gain of $2.4 million in fiscal year 2025.
• Restructuring efforts, including workforce resizing and cost actions, resulted in $11.0 million in pre-tax expense in fiscal year 2025, primarily for employee-related costs and the Tampa facility closure.
• The Board of Directors approved a plan to cease operations at the Tampa facility on November 4, 2024, with production activities transferred by June 30, 2025, and the facility classified as held for sale.
• Cash provided by operating activities significantly increased to $183.9 million in fiscal year 2025 from $73.2 million in fiscal year 2024.
• The company maintains a strong balance sheet with a current ratio of 2.2, a debt-to-equity ratio of 0.3, and Share Owners equity of $570 million as of June 30, 2025.
• Liquidity improved with $88.8 million in cash and cash equivalents and $284.7 million in unused credit facility borrowings as of June 30, 2025.
• Cash Conversion Days (CCD) improved from 100 days at June 30, 2024, to 85 days at June 30, 2025, reflecting better working capital alignment with lower sales.

Sentiment

Score: 4

Explanation: The company experienced significant declines in net sales, net income, and EPS, and a reduction in gross profit margin. While strategic restructuring and improved liquidity are positive, the overall financial performance for the fiscal year was weak, indicating challenges in the current market environment.

Positives

• Strong balance sheet maintained with a current ratio of 2.2 and a debt-to-equity ratio of 0.3 as of June 30, 2025.
• Share Owners equity increased to $570 million at June 30, 2025.
• Improved liquidity position with $88.8 million in cash and cash equivalents and $284.7 million in unused credit facility borrowings.
• Net cash provided by operating activities significantly increased to $183.9 million in fiscal year 2025, up from $73.2 million in fiscal year 2024.
• Cash Conversion Days (CCD) improved to 85 days at June 30, 2025, from 100 days at June 30, 2024, indicating better working capital management.
• Successful divestiture of the GES business on July 31, 2024, resulted in a pre-tax gain of $2.4 million and cash proceeds of $18.5 million.
• Strategic expansion of the medical CMO footprint with a new facility lease in Indiana, commencing June 2025.
• Interest expense decreased in fiscal year 2025 due to lower borrowings on credit facilities and lower interest rates.

Negatives

• Net sales decreased by 13% to $1,486.7 million in fiscal year 2025 compared to $1,714.5 million in fiscal year 2024.
• Net income decreased by 17.2% to $17.0 million in fiscal year 2025 from $20.5 million in fiscal year 2024.
• Diluted earnings per share decreased by 16% to $0.68 in fiscal year 2025 from $0.81 in fiscal year 2024.
• Gross profit as a percentage of net sales declined to 7.0% in fiscal year 2025 from 8.2% in fiscal year 2024, due to lost absorption on lower revenue.
• Sales decreased across all end market verticals: Automotive (down 11%), Medical (down 7%), and Industrial (down 24%).
• The decline in automotive sales was driven by the loss of a major automotive program and other programs reaching end-of-life.
• Medical sales decreased primarily due to lower demand resulting from customer overstocking of inventory.
• Industrial sales decreased due to the GES divestiture and declines in smart metering and public safety programs.
• Restructuring expense increased significantly to $11.0 million in fiscal year 2025 from $2.4 million in fiscal year 2024.
• The consolidated effective tax rate increased to 35.2% in fiscal year 2025 from 18.6% in fiscal year 2024, driven by limitations on business interest expense deductibility and GILTI income.
• Open orders were down 2% as of June 30, 2025, compared to June 30, 2024, which may not be indicative of future sales trends.

Risks

• Reduction of purchases by, or the loss of, one or more key customers could reduce revenues and profitability, especially given customer agreements typically do not commit to firm production schedules for more than one quarter.
• Consolidation among customers exposes the company to increased risks, including reduced revenue and dependence on a smaller number of customers, potentially leading to increased pricing and competitive pressures.
• Inability to efficiently utilize manufacturing capacity due to unpredictable customer demand levels, which can lead to declines in production, increases in excess or obsolete inventory, and reduced efficiency.
• Supply chain disruptions, including component shortages (particularly semiconductors), inflation, and shipping delays, could increase inventory costs, interrupt operations, or prevent meeting customer demand at competitive prices.
• Substantial investments required to start up and expand facilities and new customer programs may adversely affect margins and profitability if anticipated demand is not met or programs are delayed/unsuccessful.
• International operations expose the company to financial and operational risks such as economic/political instability, health emergencies, foreign currency fluctuations, warfare, compliance with foreign laws, and changes in trade policies/tariffs.
• Operating in a highly competitive industry with numerous EMS providers and in-sourcing by customers could intensify competition, impact pricing, and lower profit margins.
• Failure to meet customer quality standards in engineering and manufacturing services could lead to costs associated with product defects, production interruptions, and reputational harm.
• Harm to business due to failure to successfully implement information technology solutions or a lack of reasonable safeguards to maintain data security, including cybersecurity threats and non-compliance with data privacy laws.
• Dependence on attracting and retaining executive officers, key employees, skilled personnel, and sufficient labor, with intense competition and increasing compensation costs in the labor market.
• Failure to protect intellectual property (proprietary manufacturing technology and processes) could undermine the company's competitive position, especially in foreign countries with less protection.
• Anti-takeover provisions in organizational documents and Indiana law could delay or prevent a change in control, potentially harming stock price.
• Failure to maintain applicable registrations for manufacturing facilities, particularly as a medical device manufacturer subject to FDA and other regulatory requirements, could lead to investigations, fines, and production suspensions.
• Climate change and related legal/regulatory initiatives could subject the company to extensive environmental regulation, significant potential environmental liabilities, and increased costs for compliance and green technology investments.
• Compliance with government legislation and regulations (e.g., tariffs, conflict minerals, environmental directives) may significantly increase operating costs and negatively impact profitability.
• Exposure to the credit risk of customers, with potential for uncollectible outstanding accounts receivable due to market instability or customer bankruptcies.
• Failure to effectively manage working capital (inventory and receivables) may adversely affect cash flow from operations.
• Potential for losses due to asset impairment (facilities, equipment, intangible assets, goodwill) depending on changing business conditions.
• Fluctuations in the effective tax rate due to geographic mix of earnings, changes in tax laws, or challenges by taxing authorities.
• Exposure to foreign currency risk, with fluctuations in exchange rates potentially impacting operating results and making products more expensive.
• Failure to comply with financial covenants under credit facilities could lead to increased borrowing rates or difficulty securing future financing.
• Exposure to inflation, interest rate, and other banking and capital market risks, which could increase costs, impact pricing, and affect the ability to obtain debt financing.
• Risks associated with organic and inorganic growth, including expanding into new markets with limited operating experience and the uncertainty of achieving successful penetration or identifying suitable acquisition opportunities.
• Changes in financial accounting standards or policies may affect reported financial condition or results of operations.
• Litigation or legal proceedings could expose the company to significant liabilities and negatively impact its reputation.
• Natural disasters, pandemics, or other catastrophic events may impact production schedules, reduce employee availability, and negatively impact profitability.

Future Outlook

Management expects consolidated net sales in fiscal year 2026 to decline marginally from fiscal year 2025, primarily due to the continued impact of a major automotive program loss. Moderate growth is anticipated in the medical market for fiscal year 2026. The company plans to continue making prudent capital investments for capacity expansions and potential acquisitions to strengthen its manufacturing solutions offerings. Restructuring efforts, including the Tampa facility closure, are expected to incur additional cash expenditures of $0.5 million to $1.0 million in the first half of fiscal year 2026. Proceeds from the sale of the Tampa facility are anticipated to exceed total expected restructuring costs and the carrying value of assets held for sale.

Management Comments

• "We expect to continue to effectively operate in this market space; however, one significant challenge will be maintaining our profit margins."
• "We have a strong focus on cost control balanced with managing the future growth prospects of our business."
• "We continue to maintain a strong balance sheet as of the end of fiscal year 2025, which included a current ratio of 2.2, a debt-to-equity ratio of 0.3, and Share Owners equity of $570 million."
• "We are in a much improved liquidity position with $88.8 million in cash and unused borrowings in USD equivalent under all of our credit facilities of $284.7 million."
• "Our continuing success depends upon our ability to replace expiring customers/programs with new customers/programs."

Industry Context

The company operates in a highly competitive Electronics Manufacturing Services (EMS) industry, where it is positioned as a mid-sized player. It faces challenges from the agility and flexibility of smaller, regional players, and the scale and price competitiveness of larger, global players. The worldwide assembly market for electronics products is projected to grow at a compound annual growth rate (CAGR) of 6.3% over the next five years. Pricing in the market is competitive, with production efficiencies and material pricing advantages typically driving costs and prices down over the life of projects. The company was ranked the 24th largest global EMS provider for calendar year 2024.

Comparison to Industry Standards

• Ranked the 24th largest global EMS provider for calendar year 2024 by Manufacturing Market Insider, indicating a mid-tier position within the industry.
• Competes with major EMS companies such as Benchmark Electronics, Inc., Flex Ltd., Jabil Inc., Plexus Corp., and Sanmina Corporation.
• The company's gross profit margin of 7.0% in fiscal year 2025 is lower than the prior year, reflecting competitive pricing pressures and lower revenue absorption, a common characteristic in the competitive contract manufacturing industry.
• The company's focus on durable, high-reliability electronics and CMO solutions for automotive, medical, and industrial applications aligns with industry trends towards specialized, high-value manufacturing services.

Management Changes

Corporate Governance

Legal Proceedings

• The company and its subsidiaries are not parties to any pending legal proceedings, other than ordinary routine litigation and claims incidental to the business. The outcome of current routine pending litigation and claims, individually and in the aggregate, is not expected to have a material adverse impact on the business or financial condition.

Stakeholder Impact

• **Shareholders:** Experienced a decrease in diluted EPS and stock repurchases, but also benefit from a strong balance sheet, improved liquidity, and anti-takeover provisions designed to protect against unsolicited acquisitions. The new clawback policy enhances accountability.
• **Employees:** Subject to restructuring efforts, including workforce resizing and the closure of the Tampa facility, but the company emphasizes its 'people are the company' guiding principle, DEI&B initiatives, and continuous training and development.
• **Customers:** Faced lower demand in medical due to overstocking and loss of a major automotive program. The company aims to support global growth initiatives through its CRM model, global footprint, and expanded package of value, including medical CMO solutions.
• **Suppliers:** Impacted by supply chain disruptions, component shortages, and inflation, requiring close communication and contractual arrangements to mitigate risks. The company is committed to responsible sourcing and supply chain integrity.
• **Creditors:** Benefit from the company's strong balance sheet, improved liquidity, and compliance with financial covenants under its credit facilities, reducing credit risk.

Next Steps

• Sell the building and land of the Tampa facility, with proceeds anticipated to exceed total expected restructuring costs and carrying value.
• Continue restructuring efforts, with an estimated $0.5 million to $1.0 million in additional cash expenditures expected in the first half of fiscal year 2026.
• Make prudent capital investments for capacity expansions and potential acquisitions to support growth as a multifaceted manufacturing solutions company.
• Focus on replacing expiring customers/programs with new customers/programs to ensure sustained business success.
• Monitor current economic and industry conditions for uncertainties that may pose a threat to future growth or disrupt business strategy.

Key Dates

Recommendation

Kimball Electronics reported a significant decline in net sales and profitability for fiscal year 2025, driven by the loss of a major automotive program and customer overstocking in the medical sector. This weak financial performance is a concern. However, the company is actively addressing these challenges through strategic restructuring, including the divestiture of its GES business and the closure of the Tampa facility, while also expanding its medical CMO footprint. The balance sheet remains strong with improved liquidity and effective working capital management. Given the mixed signals of declining performance alongside proactive strategic adjustments and a solid financial foundation, a 'hold' recommendation is appropriate. Investors should monitor the execution of restructuring plans and the company's ability to replace lost programs and achieve anticipated growth in key markets.

Keywords

Electronics Manufacturing Services, CMO, Contract Manufacturing, Automotive Electronics, Medical Devices, Industrial Electronics, Supply Chain Management, Restructuring, Corporate Governance, Risk Management, SEC Filing, 10-K, Kimball Electronics, Financial Performance, Liquidity, Cybersecurity